Allworth Financial LP Has $372,000 Stake in HCA Healthcare, Inc. $HCA

HCA Healthcare reported robust Q3 earnings, with EPS of $6.96 significantly exceeding consensus estimates of $5.64 and revenue of $19.16 billion surpassing expectations. This strong performance led multiple analysts, including UBS and Mizuho, to raise price targets and reiterate 'buy' or 'outperform' ratings, contributing to a 'Moderate Buy' consensus with an average target of $474.53. Institutional investors, such as Allworth Financial LP, increased their positions, reflecting broader institutional confidence (62.73% ownership), despite some recent share sales by company executives. The company also declared a $0.72 quarterly dividend and provided optimistic FY2025 EPS guidance.

Analysis

HCA Healthcare reported robust Q3 results, significantly exceeding analyst expectations with an EPS of $6.96 against a $5.64 consensus and revenue of $19.16 billion surpassing estimates of $18.55 billion, marking a 9.6% year-over-year increase. The company also provided optimistic FY2025 EPS guidance in the $27.00-$28.00 range, signaling strong future growth.

Following these strong results, multiple research analysts, including UBS Group and Mizuho, raised price targets to $525.00 and $505.00 respectively, maintaining "buy" or "outperform" ratings, contributing to a "Moderate Buy" consensus with an average target of $474.53. Institutional investors, like Allworth Financial LP, have also increased positions, reflecting broader confidence and contributing to 62.73% institutional ownership.

However, recent insider selling by two EVPs, totaling over $3.4 million and significantly reducing their ownership stakes, presents a contrasting signal. The reported negative return on equity of 792.25% also warrants careful scrutiny, despite the stock trading at a P/E of 18.26 and a PEG ratio of 1.38. A $0.72 quarterly dividend was also declared, offering a 0.6% yield.

Key Decisions for Investors

• Investors should consider HCA's strong Q3 earnings beat and positive FY2025 guidance, which underpin the "Moderate Buy" analyst consensus and recent price target increases.
• However, the significant insider selling activity and the reported negative 792.25% return on equity warrant careful investigation into underlying causes and potential implications for long-term value.
• Monitor future insider transaction patterns and financial statements for clarification on the ROE, while factoring in the modest 0.6% dividend yield.